
|Articles|April 1, 2001
- Pharmaceutical Executive-04-01-2001
- Volume 0
- Issue 0
Liberated?
Author(s)Wayne Koberstein
Patents before profits. That soundbite snagged my ears and turned my full attention to the CNN business report. I recognized the voice and the face}Ray Gilmartin, chairman of Merck. Calmly and reasonably, he explained how extraordinary circumstances in the developing world demand that his company uncouple the normally fused objectives of high profitability and unwavering patent protection.
Advertisement
Articles in this issue
about 25 years ago
Internet DTC - Minding Your P's & Q'sabout 25 years ago
Regulation: Two-Track Planabout 25 years ago
Policy: Tectonic Shiftabout 25 years ago
A Matter of Tasteabout 25 years ago
Partnerships: Bargaining Biotechsabout 25 years ago
Pediatric Mandateabout 25 years ago
Genentech's Passion for Patientsabout 25 years ago
Regulation: OK After AllAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly’s Foundayo and Lower-Dose Zepbound Helped Maintain Weight Loss in Patients Switching from Injectables
2
Pharmaceutical Executive Daily: Rigel Pharmaceuticals Enters an Exclusive Global Licensing Agreement with Arvinas and Pfizer for Veppanu
3
Rigel Pharmaceuticals Enters $85 Million Agreement for Exclusive Global Rights to Veppanu
4
FDA Approves Beqalzi for Relapsed or Refractory Mantle Cell Lymphoma, Inqovi in Combination with Venetoclax
5




